Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%

NCT06321094 | Completed

• 1 other identifier: EVE-ACSrEF
• Study Type: observational
• Target: 149
• Locations: 1 country
• Sites: 1

Brief Summary

Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot.

Conditions

Acute Coronary Syndrome; Heart Failure With Reduced Ejection Fraction

Outcome Measures

Primary Outcomes (1)

• a composite of death from cardiovascular causes or first hospitalization for heart failure

  from baseline to one year

Secondary Outcomes (3)

• results of echocardiogram

  from baseline to one year

• the numerical value of NT-proBNP

  from baseline to one year

• life quality score

  from baseline to one year

Study Arms (2)

patients who take vericiguat

Grouped by their treatment preference, some of ACS patients with ejection fraction(EF)\<45% are to take vericiguat.

patients who donot take vericiguat

Grouped by their treatment preference, some of ACS patients with ejection fraction(EF)\<45% arenot to take vericiguat.

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

people who meet the eligibility criteria

You may qualify if:

• Provide written informed consent for the trial.
• Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction \[NSTEMI\], or ST elevation myocardial infarction \[STEMI\]) or coronary revascularization (coronary artery bypass grafting \[CABG\] or percutaneous coronary intervention \[PCI\]).
• ejection fraction \<45%.
• Be male or female, aged greater than18 and less than 90 on the day of signing informed consent.

You may not qualify if:

• SBP\<100mmHg.
• Is pregnant or breastfeeding or plans to become pregnant or to breastfeed during the course of the trial.
• Has severe hepatic insufficiency or renal insufficiency.
• Has malignancy or other non-cardiac condition limiting life expectancy to \<1 years.

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead

Study Sites (1)

the First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Location

Related Publications (4)

• Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.

  PMID: 32222134 RESULT

• Saldarriaga C, Atar D, Stebbins A, Lewis BS, Abidin IZ, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O'Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail. 2022 May;24(5):782-790. doi: 10.1002/ejhf.2468. Epub 2022 Mar 20.

  PMID: 35239245 RESULT

• Ponikowski P, Alemayehu W, Oto A, Bahit MC, Noori E, Patel MJ, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O'Connor CM, Pieske B, Roessig L, Voors AA, Westerhout C, Armstrong PW; VICTORIA Study Group. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail. 2021 Aug;23(8):1300-1312. doi: 10.1002/ejhf.2285. Epub 2021 Jul 18.

  PMID: 34191395 RESULT

• Chen T, Kong B, Shuai W, Gong Y, Zhang J, Huang H. Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling. Life Sci. 2023 Dec 1;334:122184. doi: 10.1016/j.lfs.2023.122184. Epub 2023 Oct 20.

  PMID: 37866806 RESULT

MeSH Terms

Conditions

Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2024
• First Posted: March 20, 2024
• Study Start: January 31, 2024
• Primary Completion: October 1, 2025
• Study Completion: December 1, 2025
• Last Updated: December 24, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)